Ligand Pharmaceuticals

Contributing Author

Recent Articles by Ligand Pharmaceuticals

10 hours	Ligand Reports Second Quarter 2026 Financial Results LGND GlobeNewswire
Jul-23	Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 LGND GlobeNewswire
Jul-14	Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets LGND GlobeNewswire
Jun-25	Ligand Announces Closing of Convertible Senior Notes Offering LGND GlobeNewswire
Jun-23	Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering LGND +6.59% GlobeNewswire
Jun-22	Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031 LGND GlobeNewswire
Jun-10	Ligand Announces 2026 Investor Day in New York City LGND GlobeNewswire
May-27	Ligand to Participate in June Investor Conferences LGND GlobeNewswire
May-07	Ligand Reports First Quarter 2026 Financial Results LGND -9.55% GlobeNewswire
May-05	Ligand to Participate in May Investor Conferences LGND GlobeNewswire
Apr-27	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator LGND GlobeNewswire
Apr-22	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 LGND GlobeNewswire
Apr-14	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS LGND +8.85% GlobeNewswire
Mar-26	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team LGND GlobeNewswire
Mar-04	Ligand to Participate in March Investor Conferences LGND GlobeNewswire
Feb-26	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results LGND GlobeNewswire
Feb-12	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 LGND GlobeNewswire
Feb-04	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference LGND GlobeNewswire
Dec-09	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance LGND GlobeNewswire
Nov-06	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance LGND +9.37% GlobeNewswire
Oct-30	Ligand to Participate in November Investor Conferences LGND GlobeNewswire
Oct-23	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 LGND GlobeNewswire
Oct-16	Ligand to Host Investor Day on December 9, 2025 LGND GlobeNewswire
Oct-09	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients LGND GlobeNewswire
Aug-19	Ligand to Participate in September Investor Conferences LGND GlobeNewswire
Aug-14	Ligand Announces Closing of Convertible Senior Notes Offering LGND GlobeNewswire
Aug-11	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering LGND GlobeNewswire
Aug-11	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 LGND GlobeNewswire
Aug-07	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance LGND GlobeNewswire
Jul-24	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 LGND GlobeNewswire
Jul-10	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI LGND GlobeNewswire
Jul-02	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics LGND GlobeNewswire
Jun-11	Ligand Announces 2025 Investor Day in New York City LGND GlobeNewswire
May-14	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 LGND GlobeNewswire
May-08	Ligand Reports First Quarter 2025 Financial Results LGND GlobeNewswire

Ligand Pharmaceuticals

Recent Articles by Ligand Pharmaceuticals

Upgrade your Finviz experience